Protein Kinase Inhibitor

PreclinicalSmall molecule

CCentral South University

Protein Kinase Inhibitor is one of 5 small molecule programs targeting Hepatotoxicity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatotoxicityActive, not recruiting

HepatotoxicityPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hepatotoxicity

#DrugCompanyPhaseTrials

Legalon

BBukwang Pharmaceutical

Preclinical

2 2

Tylenol

KKenvue Brands

Preclinical

1 3

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

TURALIO™

1 5

Protein Kinase Inhibitor

CCentral South University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatotoxicity1 trial

Hepatotoxicity Related to Protein Kinase Inhibitors

Unknown status·—··NCT05430126·600,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Protein Kinase Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Protein Kinase Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Protein Kinase Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentral South University

Protein Kinase Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatotoxicity1 trial

References

Drug Info

Quick Facts

Related News